Greenwich LifeSciences

General Information


We are a biopharmaceutical company developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu (human epidermal growth factor receptor 2) protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. In a Phase IIb clinical trial completed in 2018, no recurrences were observed in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months. We are planning to commence a Phase III clinical trial in 2020.

Employees: 3
Founded: 2006
Contact Information
Address 3992 Bluebonnet Dr., Building 14 Stafford, TX 77477, US
Phone Number (832) 819-3232
Web Address
View Prospectus: Greenwich LifeSciences
Financial Information
Market Cap $74.7mil
Revenues $0 mil (last 12 months)
Net Income $-3.4 mil (last 12 months)
IPO Profile
Symbol GLSI
Exchange NASDAQ
Shares (millions): 1.3
Price range $5.75 - $5.75
Est. $ Volume $7.3 mil
Manager / Joint Managers Aegis Capital Corp.
CO-Managers -
Expected To Trade: 9/25/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change